Aclaris Therapeutics
ACRS
128 hedge funds and large institutions have $1.04B invested in Aclaris Therapeutics in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 45 increasing their positions, 37 reducing their positions, and 11 closing their positions.
33% more call options, than puts
Call options by funds: $483K | Put options by funds: $362K
22% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 37
18% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 11
8% more capital invested
Capital invested by funds: $957M → $1.04B (+$78.3M)
3.32% more ownership
Funds ownership: 95.35% → 98.67% (+3.3%)
1% more funds holding
Funds holding: 127 → 128 (+1)
33% less funds holding in top 10
Funds holding in top 10: 9 → 6 (-3)
Top Buyers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$32.7M |
| 2 |
BlackRock
New York
|
+$4.48M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.07M |
| 4 |
Walleye Capital
New York
|
+$2.4M |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$2.16M |
Top Sellers
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$11.3M |
| 2 |
CC
Commodore Capital
New York
|
-$8.53M |
| 3 |
Holocene Advisors
New York
|
-$6.39M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$6M |
| 5 |
ACM
Aisling Capital Management
New York
|
-$3.22M |
ACRS Hedge Fund Activity: Q4 2022 in Review
128 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q4 2022, worth a combined $1.04B — up 8.2% from $957M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new ACRS positions and 11 closed out — a net gain of 2 holders — while 45 added to existing stakes and 37 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $32.7M. The largest seller was BVF Inc, cutting an estimated $11.3M.
- 128 institutional investors held Aclaris Therapeutics (ACRS) as of Q4 2022, up from 127 in Q3 2022.
- Funds reported $1.04B of Aclaris Therapeutics stock for Q4 2022, up 8.2% quarter-over-quarter.
- 13 funds opened new Aclaris Therapeutics positions in Q4 2022 and 11 closed out, a net change of +2 holders.
- The largest Aclaris Therapeutics buyer in Q4 2022 was Wellington Management Group, an estimated $32.7M added.
- The largest Aclaris Therapeutics seller in Q4 2022 was BVF Inc, an estimated $11.3M sold.
Based on aggregated 13F filings for Q4 2022.